Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Smith & Nephew Plc    SN.   GB0009223206


Real-time Estimate Quote. Real-time Estimate CHI-X - 01/26 04:31:02 am
1651.5 GBX   +2.51%
01/25SETTING THE STAGE : Court Sets Oral Argument In Arthrex Cases
01/19European ADRs Move Higher in Tuesday Trading
01/12European ADRs Move Higher in Tuesday Trading
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Smith & Nephew lifts revenue view after best quarter since 2015

05/02/2019 | 05:04am EST

(Reuters) - Smith & Nephew nudged up its annual revenue growth forecast on Thursday after the medical products maker reported its best quarter in more than three years on increased demand from newer markets, sending its shares up 3.5 percent.

Emerging markets, especially China, have been a bright spot for the company as its mature markets, including the United States which accounts for about half of its revenue, stabilise after a shaky start to last year.

The company, which makes hip and knee implants as well as wound care products, reported underlying sales growth of 4.4 percent in the quarter ended March 30, the highest since at least the fourth quarter of 2015.

Growth of 15.3 percent in emerging markets powered Smith & Nephew's total revenue to $1.20 billion (£919.4 million), in line with analysts' expectations, according to a company-compiled consensus http://www.smith-nephew.com/investor-centre/reporting/analyst-consensus.

Demand from emerging markets will continue to lift the company as patient populations grow and medical expertise improves, Chief Executive Officer Namal Nawana told Reuters.

"As clinicians (in emerging markets) get trained to do more sophisticated procedures like joint replacement or sports medicine procedures ... we see these as great tailwinds."

The strong first-quarter showing encouraged the company to lift its 2019 underlying growth expectation to the upper half of its previous 2.5-3.5 percent forecast range.

FTSE-100 member Smith & Nephew also benefited from 5.3 percent growth in its sports medicines unit.

Under Nawana's stewardship, Smith & Nephew - no stranger to M&A talks - has been pushing to grow through deals. The CEO was appointed in April last year in part for his deal-making expertise and knowledge of the U.S. market.

In March, Smith & Nephew bought U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million.

(Reporting by Pushkala Aripaka and additional reporting by Samantha Machado in Bengaluru; Editing by Shounak Dasgupta and Mark Potter)

By Pushkala Aripaka

© Reuters 2019
Stocks mentioned in the article
ChangeLast1st jan.
BEST INC. 7.49% 2.44 Delayed Quote.19.61%
MSCI UNITED KINGDOM (STRD, UHD) -0.78% 1061.025 Real-time Quote.3.72%
SMITH & NEPHEW PLC 2.39% 1649.5 Delayed Quote.6.69%
All news about SMITH & NEPHEW PLC
01/25SETTING THE STAGE : Court Sets Oral Argument In Arthrex Cases
01/19European ADRs Move Higher in Tuesday Trading
01/12European ADRs Move Higher in Tuesday Trading
01/12SMITH & NEPHEW : +Nephew update on fourth quarter and full year 2020 trading
01/11European ADRs Move Sharply Lower in Monday Trading
01/11SMITH & NEPHEW : Warns of Revenue, Margin Hit for 2020
01/11SMITH & NEPHEW : Expects Q4, FY20 Revenue Drop On Lower Sales, Volumes Amid COVI..
01/11SMITH & NEPHEW PLC : 4th quarter results
01/06SMITH & NEPHEW PLC : Nomination
01/05SMITH & NEPHEW : Arthrex's Initial Merits Brief – Making The Case For Pate..
More news
Financials (USD)
Sales 2020 4 582 M - -
Net income 2020 373 M - -
Net Debt 2020 1 650 M - -
P/E ratio 2020 54,6x
Yield 2020 1,29%
Capitalization 19 285 M 19 251 M -
EV / Sales 2020 4,57x
EV / Sales 2021 3,87x
Nbr of Employees 17 500
Free-Float 98,7%
Duration : Period :
Smith & Nephew Plc Technical Analysis Chart | SN. | GB0009223206 | MarketScreener
Technical analysis trends SMITH & NEPHEW PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 23,48 $
Last Close Price 22,03 $
Spread / Highest target 23,9%
Spread / Average Target 6,56%
Spread / Lowest Target -18,0%
EPS Revisions
Managers and Directors
Roland D. Diggelmann Chief Executive Officer & Non-Executive Director
Roberto Quarta Chairman
Mark Gladwell President-Global Operations & Business Services
Anne-Francoise Nesmes Chief Financial Officer & Executive Director
Vasant Padmanabhan President-Research & Development
Sector and Competitors